Celgene CorporationSummit, NJ United States
Company Description
Without cells and genes there would be no us, and without Celgene there would probably be fewer of us. The drug development company's lead product is Revlimid approved in the US and Europe as a treatment for multiple myeloma (bone marrow cancer). Revlimid also is used to treat a malignant blood disease called MDS. The company's second-biggest seller is also a treatment for MDS called Vidaza. Other marketed products include Thalomid, used in conjunction with dexamethasone to treat patients newly diagnosed with multiple myeloma, and breast cancer treatment Abraxane. The firm has other drugs in development that combat inflammatory diseases and cancer.
| 86 Morris Ave. | Phone: 908-673-9000 | http://www.celgene.com |
| Summit, NJ 07901 | Fax: 908-673-9001 | 
Map This Company |
| United States |
Try a Full Premium Subscription
Access over 85 million companies
Call (866) 443-3939 or
Prepare for your Sales call
Try a Small Business Subscription
Starting $89 per month
Celgene Corporation Rankings
| #57 in FORTUNE's Fastest-Growing Companies (September 2011) | S&P 500 | #342 in FT Global 500 (June 2011) |
Executives
| 416 executives listed for Celgene Corporation's Summit, NJ location. | ||
| Chairman, President, and CEO | Robert Hugin | |
|---|---|---|
| SVP and CFO | Jacqualyn Fouse | |
| SVP Global Regulatory Affairs, Pharmacovigilance, and Corporate Quality Assurance and Compliance | GrahamBurton | |
Financials
| Company Type | Public - NASDAQ: CELG Headquarters |
|---|---|
| Fiscal Year-End | December |
| 2011 Employees | 4,460 |
DNBiLeverage D&B's credit assessment tools to positively impact
your business. Get the scoop on Celgene Corporation now.
- Reduce risk.
- Drive greater profitability.
- Increase cash flow.
